Please click here to log in with you RCPsych web account details; you will be redirected back to CPD Online.If you have forgotten your College web account details, you will be able to reset them here.
Please click here to log in if your institution has a subscription to CPD Online with Athens access.
Please click here to log in if you are subscribed through Medicom Netherlands.
If you having troubles signing in with the options above, please try this alternative login route.
Related articles: Advances in
About the authors
Section 1: Treatment of
(1.1) Section 1: Treatment of FEP
(1.3) Interactive exercise: principles of FEP drug treatment
(1.4) Antipsychotics available in the UK for use in FEP
(1.5) Efficacy of antipsychotics in FEP
(1.7) Common antipsychotic side-effects
(1.8) Weight and metabolic parameters
(1.9) Other cardiometabolic side-effects
(1.10) Sexual side-effects and prolactin
(1.12) Interactive exercise: summary notes on the differences
between antipsychotic medications
(1.13) Clinical vignette
(1.14) Model answer
(1.15) Antipsychotics and the prevention of relapse
(1.16) Pharmacological treatment of affective presentations of
(1.17) In-patient management of FEP
(1.18) Frameworks for FEP biopsychosocial treatment
(1.19) Psychosocical treatments
(1.20) Key guidelines for the treatment of FEP
(1.21) Section 1: Recap
(1.22) Section 1:
Section 2: Outcomes and
(2.1) Section 2: Outcomes and prognosis
(2.2) Diagnoses in FEP
(2.3) Course and prognosis of FEP
(2.4) Other outcomes
(2.5) Recovery and remission
(2.6) Interactive exercise: predictors of recovery
(2.7) Do services have an effect on outcomes?
(2.8) Section 2: Recap
(2.9) Section 2:
Section 3: Models of
(3.1) Section 3: Models of care
(3.2) EIP services in the UK and worldwide
(3.3) Health policy
(3.4) EIP treatment service models
(3.5) Interactive exercise: EIP treatment service models
(3.6) EIP treatment service models
(3.7) Evidence for the effectiveness of EIP approaches
(3.8) Cost-effectiveness of EIP services
(3.9) Can EIP reduce DUP?
(3.10) Section 3: Recap
(3.11) Section 3: